Free tool
FAERS Monitor: Kygevvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219792 or its brand name (Kygevvi, Doxecitine, Doxribtimine). Reports on generic versions are filed under their own applications.
Reports
34
Serious
13
38% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea11
- off label use11
- vomiting6
- femur fracture5
- gastrostomy5
- pneumonia5
- tracheostomy5
- bradycardia3
- illness3
- tracheitis3
- anxiety2
- asthenia2
- depression2
- endotracheal intubation2
- headache2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 34 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,125 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tracheitisSignal | 3 | 2447.6 | 828.8 | 5,074 |
| tracheostomySignal | 5 | 2172.8 | 965.4 | 8,761 |
| gastrostomySignal | 5 | 2002.7 | 890.0 | 8,076 |
| endotracheal intubation | 2 | 441.7 | 115.1 | 494 |
| femur fractureSignal | 5 | 99.9 | 44.5 | 396 |
| bradycardiaSignal | 3 | 35.0 | 11.9 | 68 |
| illnessSignal | 3 | 18.0 | 6.1 | 33 |
| diarrhoeaSignal | 11 | 10.5 | 6.5 | 88 |
| pneumoniaSignal | 5 | 9.6 | 4.3 | 31 |
| vomitingSignal | 6 | 7.9 | 3.8 | 30 |
| off label useSignal | 11 | 7.8 | 4.8 | 61 |
| depression | 2 | 5.4 | 1.4 | 4 |
| anxiety | 2 | 4.3 | 1.1 | 2 |
| asthenia | 2 | 3.3 | 0.9 | 1 |
| headache | 2 | 2.0 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.